

BAF53 (B-1): sc-137063

BACKGROUND

The SWI/SNF complex regulates gene expression via ATP-dependent chromatin remodeling. Brm (SNF2- α), Brg-1 (SNF2- β), Ini1 (integrase interactor 1, SNF5), BAF53 (ARPN β), BAF57, BAF155 (SRG3) and BAF170 make up the functional core. BAF53 homologues from yeast to humans contain a conserved N-terminal motif, which contains residues at Serine 2 and Tyrosine 6, which play important roles in BAF53 activity. The BAF53 protein shuttles between the nucleus and cytoplasm. BAF53 also forms a complex with TIP49 and TIP48, which mediates c-Myc oncogenic activity.

CHROMOSOMAL LOCATION

Genetic locus: ACTL6A (human) mapping to 3q26.33; Actl6a (mouse) mapping to 3 A3.

SOURCE

BAF53 (B-1) is a mouse monoclonal antibody specific for an epitope mapping between amino acids 87-129 near the N-terminus of BAF53 of human origin.

PRODUCT

Each vial contains 200 μ g IgG_{2a} kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Also available as TransCruz reagent for Gel Supershift and ChIP applications, sc-137063 X, 200 μ g/0.1 ml.

Blocking peptide available for competition studies, sc-137063 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% stabilizer protein).

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

BAF53 (B-1) is recommended for detection of BAF53 of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

BAF53 (B-1) is also recommended for detection of BAF53 in additional species, including canine, bovine and porcine.

Suitable for use as control antibody for BAF53 siRNA (h): sc-60239, BAF53 siRNA (m): sc-60240, BAF53 shRNA Plasmid (h): sc-60239-SH, BAF53 shRNA Plasmid (m): sc-60240-SH, BAF53 shRNA (h) Lentiviral Particles: sc-60239-V and BAF53 shRNA (m) Lentiviral Particles: sc-60240-V.

BAF53 (B-1) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.


Molecular Weight of BAF53: 45 kDa.

Positive Controls: Hep G2 cell lysate: sc-2227, NIH/3T3 whole cell lysate: sc-2210 or BW5147 cell lysate: sc-3800.


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850. 4) Immunohistochemistry: use m-IgG κ BP-HRP: sc-516102 with DAB, 50X: sc-24982 and Immunohistomount: sc-45086, or Organo/Limonene Mount: sc-45087.

DATA



BAF53 (B-1): sc-137063. Western blot analysis of BAF53 expression in Hep G2 (A), RT-4 (B), NIH/3T3 (C), BW5147 (D), NRK (E) and C6 (F) whole cell lysates.



BAF53 (B-1): sc-137063. Immunofluorescence staining of methanol-fixed HeLa cells showing nuclear localization (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded human spleen tissue showing nuclear and cytoplasmic staining of cells in the white and red pulps (B).

SELECT PRODUCT CITATIONS

1. Wang, Z., et al. 2020. Dual ARID1A/ARID1B loss leads to rapid carcinogenesis and disruptive redistribution of BAF complexes. *Nat. Cancer* 1: 909-922.
2. Yao, X., et al. 2023. PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF κ B pathway in clear cell renal cell carcinoma. *Nat. Cell Biol.* 25: 765-777.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.